GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
GO:00427529 | Esophagus | ESCC | regulation of circadian rhythm | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:0000086 | Liver | HCC | G2/M transition of mitotic cell cycle | 75/7958 | 137/18723 | 2.52e-03 | 1.22e-02 | 75 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
GO:0044839 | Liver | HCC | cell cycle G2/M phase transition | 79/7958 | 148/18723 | 4.82e-03 | 2.03e-02 | 79 |
GO:0031146 | Liver | HCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXL6 | SNV | Missense_Mutation | | c.712C>G | p.Leu238Val | p.L238V | Q8N531 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXL6 | SNV | Missense_Mutation | rs201944090 | c.1222N>T | p.Arg408Trp | p.R408W | Q8N531 | protein_coding | tolerated(0.05) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FBXL6 | SNV | Missense_Mutation | | c.1526N>A | p.Arg509His | p.R509H | Q8N531 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
FBXL6 | deletion | Frame_Shift_Del | novel | c.614delN | p.Lys205SerfsTer8 | p.K205Sfs*8 | Q8N531 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
FBXL6 | SNV | Missense_Mutation | novel | c.1519N>C | p.Ser507Pro | p.S507P | Q8N531 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXL6 | SNV | Missense_Mutation | | c.491N>T | p.Ser164Phe | p.S164F | Q8N531 | protein_coding | tolerated(0.78) | benign(0.382) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXL6 | SNV | Missense_Mutation | novel | c.818G>A | p.Arg273Gln | p.R273Q | Q8N531 | protein_coding | tolerated(0.37) | possibly_damaging(0.903) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
FBXL6 | SNV | Missense_Mutation | | c.1387N>A | p.Ala463Thr | p.A463T | Q8N531 | protein_coding | tolerated(0.15) | benign(0.17) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXL6 | SNV | Missense_Mutation | rs782380191 | c.1493N>T | p.Pro498Leu | p.P498L | Q8N531 | protein_coding | deleterious(0.01) | benign(0.11) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXL6 | SNV | Missense_Mutation | rs372210529 | c.1174N>T | p.Arg392Cys | p.R392C | Q8N531 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |